Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study
Interim data showed that pembrolizumab showed statistically significant improvement in progression-free survival compared with brentuximab vedotin (n=304; 13.2 vs 8.3 months; HR, 0.65; 95% CI 0.48–0.88; p=0.0027).
Source:
The Lancet Oncology